• Protease Inhibitor Cocktail (EDTA-Free, 200X): Technical Use

  2026-05-31

  Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is formulated to prevent protein degradation during extraction without introducing EDTA, making it suitable for workflows sensitive to divalent cations. It is not recommended for protocols requiring metalloprotease inhibition via EDTA. Researchers working with phosphorylation analysis, Western blotting, or enzyme assays benefit from its compatibility and ready-to-use formulation.

• Sodium-Induced Mitochondrial Dysfunction Drives NECSO Pathol

  2026-05-30

  This article examines recent findings on how sodium influx disrupts mitochondrial energy metabolism to execute necrosis by sodium overload (NECSO). The study reveals a mechanistic link between TRPM4-mediated Na+ entry, mitochondrial dysfunction, and energy crisis, with broad implications for cell death research.

• Lycium barbarum Polysaccharide Restores Muscle via AMPK-Mito

  2026-05-29

  This study reveals that Lycium barbarum polysaccharide (LBP) attenuates skeletal muscle atrophy in high-fat diet-induced sarcopenic obesity by activating the AMPK/PINK1/Parkin-mediated mitophagy pathway. The findings highlight a mechanistic link between energy metabolism regulation, mitochondrial quality control, and muscle preservation, with implications for metabolic disease research.

• XPO1 Inhibition Sensitizes GCB-DLBCL to Platinum Chemotherap

  2026-05-29

  This study demonstrates that targeting XPO1 with selinexor enhances the efficacy of platinum-based chemotherapy in germinal-center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) models. The findings provide mechanistic evidence for combining XPO1 inhibitors with platinum agents to overcome drug resistance and improve therapeutic outcomes in aggressive B-cell lymphomas.

• RG108 (SKU A1913): Precision DNMT Inhibition for Reliable As

  2026-05-28

  This article addresses recurrent laboratory challenges in epigenetic research and cell-based assays, focusing on the application of RG108 (SKU A1913) as a potent, non-nucleosidic DNA methyltransferase inhibitor. Through real-world scenarios and data-driven answers, we demonstrate how RG108 from APExBIO enhances reproducibility, sensitivity, and workflow confidence for biomedical researchers, particularly in tumor suppressor gene reactivation and DNA demethylation experiments.

• AI-Based Urine Stem Cell Mitochondria Analysis for Alzheimer

  2026-05-28

  This reference study establishes a deep learning framework to assess mitochondrial morphology in urine-derived stem cells as a non-invasive biomarker for Alzheimer’s disease. The approach enables dynamic, patient-specific evaluation of mitochondrial dysfunction, marking a significant advance over current invasive or static diagnostic methods.

• Amyloid Beta-peptide (25-35): Precision Tools for Microglial

  2026-05-27

  Explore how Amyloid Beta-peptide (25-35) (Aβ25-35) enables mechanistic dissection of microglial polarization and neuroinflammation in Alzheimer's disease. This article integrates translational insights, protocol guidance, and a competitive landscape review, empowering researchers to advance neurodegenerative disease modeling with reproducibility and impact.

• Praeruptorin A Inhibits HCC Metastasis via ERK/MMP1 Pathway

  2026-05-27

  This study reveals that Praeruptorin A suppresses the metastasis of human hepatocellular carcinoma (HCC) cells by downregulating MMP1 through ERK pathway activation, without inducing cytotoxicity. The findings highlight a pathway-selective, non-cytotoxic mode of action, suggesting new avenues for targeted therapies and model development in liver disease research.

• Morin Inhibits AMPD2 to Restore Podocyte Mitochondria in Fru

  2026-05-26

  Yang et al. (2025) reveal that Morin, a natural flavonoid compound, protects glomerular podocytes from fructose-induced mitochondrial dysfunction by inhibiting adenosine 5′-monophosphate deaminase (AMPD2). This mechanistic insight positions Morin as a potential research tool for dissecting metabolic injury in kidney disease models.

• BMS-345541 and Precision NF-κB Pathway Modulation in Vascula

  2026-05-26

  Explore how BMS-345541, a selective IKK-1/IKK-2 inhibitor, is advancing inflammation and angiogenesis research with unique mechanistic insights and practical protocol guidance. Discover new perspectives on cytokine suppression and apoptosis induction in cancer cells.

• Biotin-16-UTP: Practical Guide to RNA Detection and Purifica

  2026-05-25

  Biotin-16-UTP is a biotin-labeled uridine triphosphate for efficient RNA labeling during in vitro transcription, enabling downstream detection, purification, and interaction studies. It is best suited for molecular biology workflows requiring high-affinity biotin-streptavidin capture, but should not be used in diagnostic or clinical applications.

• Parathyroid hormone (1-34) (human): Precision in Bone and Ki

  2026-05-25

  Parathyroid hormone (1-34) (human) unlocks high-fidelity modeling of bone metabolism and kidney disease, particularly in dissecting PTH/PTHrP receptor signaling and calcium homeostasis. This article provides advanced experimental workflows, troubleshooting guidance, and cross-study insights to maximize reproducibility and translational impact.

• Nav1.6 and NHE1 Drive Glioblastoma Proliferation and Migrati

  2026-05-24

  This study uncovers how voltage-gated sodium channel Nav1.6 and Na+/H+ exchanger-1 (NHE1) cooperatively promote glioblastoma proliferation, migration, and survival through ERK/AKT signaling. Targeting both proteins may offer a strategic pathway for inhibiting tumor growth and inducing apoptosis in glioblastoma cells.

• Urolithin A: Optimized Workflows for Mitochondrial Biogenesi

  2026-05-23

  Urolithin A unlocks new experimental avenues for mitochondrial quality control and liver fibrosis studies, thanks to its precision as a mitophagy activator and robust anti-inflammatory profile. This article distills evidence-backed workflows, troubleshooting insights, and advanced protocol parameters to help researchers extract maximal value from APExBIO’s high-purity 3,8-dihydroxy-6H-benzo[c]chromen-6-one.

• Anlotinib in IADSRCT: Case Evidence for Multi-Target TKI Eff

  2026-05-22

  This article reviews the first reported use of anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, in treating intra-abdominal desmoplastic small round cell tumor (IADSRCT). The study demonstrates meaningful tumor regression and manageable toxicity, offering a new therapeutic avenue for this rare, treatment-resistant sarcoma.

15304 records 1/1021 page Next 12345 下5页 Last page